Genmab (GMAB)
(Real Time Quote from BATS)
$28.18 USD
-0.17 (-0.60%)
Updated Aug 2, 2024 02:18 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Genmab A/S Sponsored ADR (GMAB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$41.13 | $53.00 | $29.00 | 45.08% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Genmab A/S Sponsored ADR comes to $41.13. The forecasts range from a low of $29.00 to a high of $53.00. The average price target represents an increase of 45.08% from the last closing price of $28.35.
Analyst Price Targets (8 )
Broker Rating
Genmab A/S Sponsored ADR currently has an average brokerage recommendation (ABR) of 2.12 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 2.18 a month ago based on 17 recommendations.
Of the 17 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 52.94% and 5.88% of all recommendations. A month ago, Strong Buy represented 52.94%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 1 | 1 | 0 | 0 | 0 |
Hold | 5 | 5 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.12 | 2.12 | 2.18 | 2.18 | 2.18 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/15/2024 | Not Identified | Not Identified | Hold | Moderate Buy |
6/27/2024 | BTIG | Kaveri Pohlman | Strong Buy | Strong Buy |
6/20/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
6/6/2024 | SVB Securities | Jonathan W Chang | Hold | Hold |
6/3/2024 | William Blair | Matt Phipps | Hold | Hold |
4/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Hold | Hold |
3/26/2024 | Truist Securities | Asthika S Goonewardene | Strong Buy | Strong Buy |
2/23/2024 | BMO Capital Markets | Etzer Darout | Hold | Strong Buy |
1/22/2024 | Not Identified | Not Identified | Hold | Strong Sell |
12/6/2023 | UBS | Xian Deng | Hold | Strong Buy |
11/8/2023 | Guggenheim Securities | Michael Schmidt | Not Available | Hold |
10/18/2023 | Exane BNP Paribas | Victor Floch | Not Available | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.12 |
ABR (Last week) | 2.12 |
# of Recs in ABR | 17 |
Average Target Price | $41.13 |
LT Growth Rate | 24.80% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 88 of 253 |
Current Quarter EPS Est: | 0.29 |